SCHEMBL25232250

SCHEMBL25232250

CCn1c(-c2ccncc2)nc2c(N3CCOCC3)nc(-n3ccc(C4CCCOC4)n3)nc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 13/20 0.45
▸ ALDH1A1 P00352 13/20 0.45
▸ HPGD P15428 13/20 0.45
▸ HSD17B10 Q99714 13/20 0.45
▸ CYP3A4 P08684 9/20 0.45
▸ TSHR P16473 3/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ CASP1 P29466 1/20 0.39
▸ PDE10A Q9Y233 2/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ ADORA3 P0DMS8 1/20 0.34
▸ ADORA2A P29274 1/20 0.34
▸ ADORA2B P29275 1/20 0.34
▸ ADORA1 P30542 1/20 0.34
▸ KMT2A Q03164 1/20 0.33
▸ HDAC3 O15379 1/20 0.33
▸ HDAC4 P56524 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC7 Q8WUI4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25276103 0.92 KDM4E (0.44) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL30254842 0.85 KDM4E (0.37) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL25733481 0.85 KDM4E (0.37) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL25235973 0.82 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL25733517 0.81 KDM4E (0.45) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL31730846 0.81 KDM4E (0.45) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL31730977 0.81 KDM4E (0.38) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL25733537 0.81 KDM4E (0.38) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL25230690 0.80 KDM4E (0.44) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL25274245 0.80 KDM4E (0.39) KDM4EALDH1A1HPGDHSD17B10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353851-A1 PURINES AND METHODS OF THEIR USE KINETA INC (US) 2025-11-20 — — US disclosed
CN-119031913-A Purine and methods of use thereof 奇尼塔公司 2024-11-26 — — CN disclosed
EP-4444312-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 — — EP disclosed
WO-2023107552-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 — — WO disclosed
WO-2023107552-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353851-A1 PURINES AND METHODS OF THEIR USE TDP1, TDP2, PIKFYVE KDM4E 870/4885ALDH1A1 4617/4885HPGD 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback